Article - 07/02/2011 The discovery of the individual as business model The move towards personalised medicine has made considerable progress, in particular in the field of oncology, where it is leading to the close integration of diagnostics and therapy as well as to the development of profitable new business models, some of which have controversial exclusive legal claims.https://www.gesundheitsindustrie-bw.de/en/article/news/the-discovery-of-the-individual-as-business-model
Press release - 03/02/2011 A Possible Cause of Parkinson’s Disease Discovered When a person has Parkinsons disease the dopamine-producing nerve cells in the brain die which leads to the characteristic symptoms of this neurological disorder. Scientists of the German Cancer Research Center Deutsches Krebsforschungszentrum DKFZ have discovered that this group of nerve cells of patients with Parkinsons contains defective nucleoli.https://www.gesundheitsindustrie-bw.de/en/article/press-release/a-possible-cause-of-parkinson-s-disease-discovered
Press release - 02/02/2011 Electric Signals Amplify Weak Olfactory Stimuli in the Nose The human olfactory system possesses a special electric amplification mechanism that enables olfactory cells to respond even to extremely weak stimuli. Scientists at Heidelberg University headed by physiologist Prof. Dr. Stephan Frings have now established how this mechanism works. Crucial is the role played by chloride ions stored in the sensory cilia of the nose. As soon as the olfactory receptors in the sensory cilia detect odorants the…https://www.gesundheitsindustrie-bw.de/en/article/press-release/electric-signals-amplify-weak-olfactory-stimuli-in-the-nose
Article - 31/01/2011 Technische Universität Braunschweig – made-to-measure synthetic microorganisms The Institute of Biochemical Engineering at Technische Universität Braunschweig (Technical University (TU) Braunschweig) is a member of the Biopolymers/Biomaterials cluster and, as such, is involved in two projects to produce diaminopentane and succinic acid using optimised microorganisms with the aim of establishing a basis from which to provide industry with new materials made from renewable resources.https://www.gesundheitsindustrie-bw.de/en/article/news/technische-universitaet-braunschweig-made-to-measure-synthetic-microorganisms
Press release - 31/01/2011 Researchers from Stuttgart decipher the function of antibiotics that are naturally produced by the human body Researchers at the Robert Bosch Hospital RBK and the Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology IKP in Stuttgart have now deciphered a new mechanism of action of the human immune system that protects against intestinal bacteria and pathogenic yeasts. The internationally renowned scientific journal Nature presents their findings.https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-from-stuttgart-decipher-the-function-of-antibiotics-that-are-naturally-produced-by-the-h
Press release - 30/01/2011 Door opener for influenza viruses An international group of researchers, including scientists from the University of Tübingen, has deciphered mechanisms that enable the initiation and also the inhibition of influenza virus infections. The importin alpha-7 variant plays a crucial role in the ability of influenza A viruses to infect humans.https://www.gesundheitsindustrie-bw.de/en/article/press-release/door-opener-for-influenza-viruses
Press release - 26/01/2011 Uncovering the Genetics of Prostate Cancer Germany will contribute another project to the International Cancer Genome Consortium ICGC. Coordinated by the German Cancer Research Center and the University Medical Center Hamburg-Eppendorf physicians and molecular biologists will now start to investigate the genetic causes of early prostate cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/uncovering-the-genetics-of-prostate-cancer-1
Press release - 26/01/2011 ‘Complexes Matter’ in How Epigenetic Inhibitors Interact with Their Drug Targets Cellzome Scientists Publish First Chemoproteomic Characterization of HDAC Inhibitors in Nature Biotechnology. Results of the first ever chemoproteomic study of inhibition of HDAC Histone Deacetylase complexes opens up the potential for a new way of studying potency and selectivity for inhibitors of epigenetic drug targets such as HDACs. https://www.gesundheitsindustrie-bw.de/en/article/press-release/complexes-matter-in-how-epigenetic-inhibitors-interact-with-their-drug-targets
Press release - 26/01/2011 Boehringer Ingelheim to Purchase Amgen’s Fremont (USA) Facility Amgen Inc. and Boehringer Ingelheim today announced they have signed an agreement under which Boehringer Ingelheim will acquire Amgen’s rights in substantially all assets at Amgen’s Fremont California development and manufacturing facility.https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-to-purchase-amgen-s-fremont-usa-facility
Article - 24/01/2011 Protzek GmbH: On site drug testing and analytics How do you find out if someone is driving under the influence of alcohol or drugs? Up until now the police had to visually inspect and assess test strips in order to convict a drunken or doped driver. Lörrach-based Protzek Gesellschaft für Biomedizinische Technik mbH have improved this situation with the development of a mobile system that uses objective criteria to quantitatively analyse drugs and medications on site. https://www.gesundheitsindustrie-bw.de/en/article/news/protzek-gmbh-on-site-drug-testing-and-analytics
Press release - 24/01/2011 Synimmune - Close cooperation cuts new cancer drug development time A development project from Synimmune GmbH, founded in July 2010, made a big impression on the panel of assessors at the German Federal Ministry of Education and Research (BMBF). So much so, that the company was awarded EUR 2.5 million as part of the GO-Bio biotechnology start-up scheme. https://www.gesundheitsindustrie-bw.de/en/article/press-release/synimmune-close-cooperation-cuts-new-cancer-drug-development-time
Press release - 24/01/2011 Dangerous Starting Signal for Intestinal Stem Cells The mucosal lining of the intestine is renewed every two to five days. In this process stem cells in the intestine replace cells of the gut epithelium which have been lost due to injury or normal wear and tear by new cells. New findings show tha the cellular EGFR signaling pathway plays an important role in this process It stimulates stem cells to divide so that their daughter cells replace the damaged intestinal epithelium. This signaling…https://www.gesundheitsindustrie-bw.de/en/article/press-release/dangerous-starting-signal-for-intestinal-stem-cells
Press release - 23/01/2011 Effective treatment of chronic myeloid leukaemia seems attainable The European LeukemiaNet ELN an EU-funded organisation of physicians scientists and patients with an interest in leukaemia has an important goal the successful treatment of leukaemia. This goal is shared by the pharmaceutical company Novartis. The company will now invest another 6 million euros in the already successful project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/effective-treatment-of-chronic-myeloid-leukaemia-seems-attainable
Press release - 19/01/2011 Colonoscopy Provides Protection from Cancer on Both Sides of the Colon Scientists of the German Cancer Research Center DKFZ in Heidelberg have now shown that inspection of both sides of the colon also reduces cancer risk in the right part of the colon by more than 50 percent. The overall risk was found to be 77 percent lower. This means that colonoscopy provides very good protection from colon cancer - even though it is not a 100 percent guarantee.https://www.gesundheitsindustrie-bw.de/en/article/press-release/colonoscopy-provides-protection-from-cancer-on-both-sides-of-the-colon
Press release - 19/01/2011 Baden-Württemberg funds innovative ideas in biotechnology and medical technology The Baden-Württemberg government is planning to exploit the enormous research potential in the fields of biotechnology and medical technology even better than in the past. As part of this objective, the Baden-Württemberg Ministry of Science, Research and the Arts launched an idea competition for which a jury has now selected 42 winning projects. The winners are now being given the opportunity to test their ideas in feasibility studies. The…https://www.gesundheitsindustrie-bw.de/en/article/press-release/baden-wuerttemberg-funds-innovative-ideas-in-biotechnology-and-medical-technology
Article - 18/01/2011 Innovation hotspots In December 2010, the German and Israeli Ministers of Economics, Rainer Brüderle and Binyamin Ben-Eliezer, jointly opened the German-Israeli Innovation Day. The motto of the annual conference organised by the German-Israeli Life Sciences Committee in Heidelberg was “New ideas for a healthier world”. The conference enabled German participants to expand and reinforce their contacts with Israeli companies based on the long-standing cooperation…https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-hotspots
Article - 17/01/2011 nadicom GmbH: novel strategies to prove microcrobes guilty Microscopic life is omnipresent and it also appears in places where it is not wanted. The Karlsruhe-based nadicom Gesellschaft für angewandte Mikrobiologie mbH offers a broad range of services to companies and environmental authorities to help them deal with and control the omnipresence of microorganisms.https://www.gesundheitsindustrie-bw.de/en/article/news/nadicom-gmbh-novel-strategies-to-prove-microcrobes-guilty
Article - 17/01/2011 Atoll GmbH to supply ready-to-use solutions for biopharmaceutical separation processes Atoll GmbH has developed a miniaturised chromatography platform that facilitates and accelerates complex biopharmaceutical production processes. Process developers from research and development laboratories around the world appreciate the time and cost savings that can be achieved with Atoll’s chromatography tools as well as the technology’s ability to specifically isolate sought-after compounds. The current huge demand for this technology means…https://www.gesundheitsindustrie-bw.de/en/article/news/atoll-gmbh-to-supply-ready-to-use-solutions-for-biopharmaceutical-separation-processes
Article - 12/01/2011 How milk, cheese, yoghurt and curd cheese can be kept free from “genetic engineering” Bacteriophages introduce their DNA into bacteria where they quickly reproduce and eventually destroy the host organism. Phages are omnipresent in nature and some can be dangerous for humans. They also represent a huge contamination risk in the production of fermented food. Canadian researchers Lvesque et al. 2005 estimate that phages cause around 10 per cent of all production losses in the diary industry where they infest bacteria such as…https://www.gesundheitsindustrie-bw.de/en/article/news/how-milk-cheese-yoghurt-and-curd-cheese-can-be-kept-free-from-genetic-engineering
Press release - 10/01/2011 The first Salome Gluecksohn-Waelsch Prize laureate SGBM and the Department of Genetics at Albert Einstein College of Medicine, New York select the best dissertation submitted to SGBM in 2010. The winner is Markus Mordstein. https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-first-salome-gluecksohn-waelsch-prize-laureate
Press release - 10/01/2011 Nycomed: Daxas® included as a treatment option in COPD guidelines The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has included roflumilast (Daxas®) as a new treatment option in its COPD management guidelines. A section on the new class, phosphodiesterase 4 (PDE4) inhibitors, describes the efficacy of roflumilast in patients with COPD.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-daxas-included-as-a-treatment-option-in-copd-guidelines
Article - 10/01/2011 Review: What does the cell factory of the future look like? A symposium on “Cell Factories of the Future” was held at the Laupheim-based company Rentschler Biotechnologie on 14th and 15th October 2010. The event attracted around 70 scientists from academia and industry and will now take place every two years. The symposium focused on new biomanufacturing developments and technologies, and included lectures on (animal) cells, cell factories and the future of recombinant protein production. https://www.gesundheitsindustrie-bw.de/en/article/news/review-what-does-the-cell-factory-of-the-future-look-like
Press release - 09/01/2011 Baden-Württemberg Research and Development Monitor In 2007 the RD expenditures of industrial research institutions universities and publicly funded RD institutions reached a record high. As much as one quarter of German RD expenditures were incurred in Baden-Württemberg which shows that Baden-Württemberg is further expanding its strong position. The majority of the research in Baden-Württemberg is carried out by industrial companies. https://www.gesundheitsindustrie-bw.de/en/article/press-release/baden-wuerttemberg-research-and-development-monitor
Press release - 08/01/2011 Sense2care - new dimension of blood gas analysis systems Established in August 2010 at the Natural and Medical Sciences Institute at the University of Tübingen (NMI) in Reutlingen, sense2care is an innovative medical technology company. The High-Tech Foundation Fund has now awarded sense2care a total of €500,000 for investing in the development of miniaturised systems to monitor critically ill patients in the operating theatre and in intensive care. https://www.gesundheitsindustrie-bw.de/en/article/press-release/sense2care-new-dimension-of-blood-gas-analysis-systems
Article - 20/12/2010 Michael Reth – Immunobiological discoveries that meet resistance Dr Michael Reth professor at the Max Planck Institute of Immunobiology and the University of Freiburg and some of his colleagues have recently uncovered the mechanism that foreign substances use to activate B cells of the immune system. The researchers were using synthetic biology methods long before this particular branch of science existed in its present form. Their results require a paradigm change and a revision of the reference books.https://www.gesundheitsindustrie-bw.de/en/article/news/michael-reth-immunobiological-discoveries-that-meet-resistance